TCB Team is a group of domain experts and writers focused on biotech, healthcare, and AI. They deliver original, high-signal coverage tailored for industry professionals, investors, and researchers. With a neutral and independent voice, the team transforms complex developments into clear, actionable insights.
110 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe study highlights consequential public health impacts stemming from policy changes, underlining critical gaps in preventive cancer care access for vulnerable populations.
TCB TeamJan 9, 2026
Healthcare InvestmentFormer New Mountain Capital executive Matt Holt explores combining five health tech startups into the 'Thoreau' platform, seeking to streamline services across payers, providers, and data. If successful, this ambitious project would rank among the largest private equity-backed ventures in health tech.
TCB TeamJan 9, 2026
Biopharmaceutical IndustryEli Lilly has acquired Ventyx Biosciences for $1.2 billion to bolster its drug pipeline with an oral NLRP3 inhibitor showing promising mid-stage clinical data. Potential applications span cardiovascular disease, Parkinson’s disease, and autoimmune conditions, reinforcing Lilly's position in inflammation-focused therapies.
TCB TeamJan 9, 2026
Biotech InnovationAlveus Therapeutics recently secured $160 million to advance a Phase 2-ready drug tackling obesity through dual GLP-1 and GIP receptor modulation. The startup's approach may offer dosing advantages and compete with established pharma players like Amgen, Roche, and Novo Nordisk.
TCB TeamJan 9, 2026
Healthcare InvestmentThe significant funding round by Parabilis Medicines exemplifies renewed investor interest in oncology drug development, amid a broader wave of biotech financing involving several other emerging companies this January.
TCB TeamJan 8, 2026
Regulatory & PolicyWith increasing backing from House Republicans, particularly those representing vulnerable districts, the subsidy extension aims to ease rising insurance premium costs. This development marks a pivotal moment in ongoing healthcare policy negotiations for 2026.
TCB TeamJan 8, 2026
Regulatory & PolicyA recently published study in Science attributes the sharp decline in overdose fatalities to changes in the fentanyl supply, highlighting implications for public health strategies addressing the opioid crisis.
TCB TeamJan 8, 2026
AI in Drug DiscoveryThe new offering represents a significant development in AI-driven healthcare interactions, reflecting regulatory shifts as the FDA pursues a deregulatory stance on AI and digital health tools.
TCB TeamJan 8, 2026
Regulatory & PolicyThe investigation focuses on potential limitations imposed by UnitedHealth on hospitalizations, which could affect patient health outcomes and adherence to Medicare regulations. This expands ongoing scrutiny of managed care practices.
TCB TeamJan 8, 2026
Regulatory & PolicyThe court's decision pauses the rollout of a controversial pilot that aimed to reform drug pricing for hospitals under the 340B program. This legal development underscores persistent challenges in federal drug rebate policies.
TCB TeamJan 8, 2026
Healthcare InvestmentThe funding round led by Parabilis highlights the strong biotech fundraising environment as several companies have attracted significant capital recently. These investments underpin ongoing efforts to develop innovative cancer treatments.
TCB TeamJan 8, 2026
Healthcare InvestmentThe surge in mergers and acquisitions within obesity and diabetes therapeutics marked a major investment shift in 2025, reflecting increased market confidence in these disease areas despite broader funding challenges.
TCB TeamJan 8, 2026